Athos Therapeutics collaborates with Vultr for AI-driven precision medicine development

Athos Therapeutics, a clinical-stage biotechnology company specialising in AI-driven precision therapeutics for immune-mediated diseases and cancer, has chosen Vultr's Cloud GPU platform for its AI model training.

Athos, is at the forefront of using AI and machine learning to develop small-molecule therapeutics. To understand the complexities of autoimmune diseases and cancer at the molecular level, Athos collaborates with prominent hospitals, such as the Cleveland Clinic and Lahey Hospital & Medical Center, conducting multi-omics analysis on over 25,000 patients. Additionally, the company works with Caltech to perform proteomics using patient samples.

To advance its research, Athos required a cost-effective, flexible, and high-performance cloud solution to ensure its data's security and confidentiality. Vultr's Cloud GPU, powered by NVIDIA HGX H100 systems and Dell Technologies' PowerEdge servers, was chosen to meet these needs, offering robust AI model training, tuning, and inference support.

Amit Rai, General Manager of AI and Enterprise Cloud at Vultr, highlighted the significance of this partnership:

“Enabling the next wave of innovators is core to our mission of democratizing access to high-performance cloud compute. And for a company like Athos, which operates in a highly regulated industry, security and compliance are top considerations for maintaining operational excellence.

“We are proud to be working with Athos, providing the scalable, performant, safe, and secure infrastructure that will underpin their platform, as the company continues to scale and deliver life-changing therapeutics for patients around the world.”

Athos' autonomous AI analytical platform, which includes the Athos data lake and a deep machine learning engine, will benefit from Vultr's infrastructure. This setup will allow the company to train large datasets while ensuring compliance with data sovereignty and privacy regulations. This setup promises to enhance productivity and reduce downtime, which is critical for ongoing research and development.

Travis Vigil, Senior Vice President of ISG Product Management at Dell Technologies, stated:

"Breakthrough medical research requires dynamic, reliable computing power. With Vultr's cloud platform running on Dell PowerEdge XE9680 servers, we're helping enable Athos to run AI workloads at scale securely and pioneer precision small molecule therapeutics that could improve countless lives."

Athos' choice of Vultr's AI cloud platform offers several advantages, including scalable GPU resources, a user-friendly interface, continuous monitoring and management, and robust security. These features ensure efficient and effective AI training, supporting Athos' mission to develop novel precision therapeutics.

Dimitrios Iliopoulos, PhD, MBA, President & CEO of Athos, expressed his enthusiasm for the collaboration: “Athos is on a mission to provide novel precision therapeutics for patients with autoimmune diseases and cancer. We are excited to collaborate with Vultr and Dell to empower our AI computational team to achieve this goal by leveraging the power of NVIDIA H100 GPUs at scale. With Vultr’s support, we have been able to minimise downtime and maximise productivity throughout the business.”